NASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free BTMD Stock Alerts $5.75 -0.09 (-1.54%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.75▼$5.9450-Day Range$5.30▼$6.9152-Week Range$3.65▼$8.22Volume55,373 shsAverage Volume83,857 shsMarket Capitalization$356.73 millionP/E Ratio52.27Dividend YieldN/APrice Target$8.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get biote alerts: Email Address biote MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.0% Upside$8.11 Price TargetShort InterestBearish3.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.21 out of 5 starsMedical Sector557th out of 921 stocksMedicinals & Botanicals Industry4th out of 11 stocks 3.5 Analyst's Opinion Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coveragebiote has only been the subject of 2 research reports in the past 90 days.Read more about biote's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.25% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in biote has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTMD. Previous Next 2.5 News and Social Media Coverage News Sentimentbiote has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for biote this week, compared to 1 article on an average week.MarketBeat Follows2 people have added biote to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biote insiders have not sold or bought any company stock.Percentage Held by Insiders13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for biote are expected to remain at $0.52 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 52.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.21.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 52.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.67.Read more about biote's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About biote Stock (NASDAQ:BTMD)biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More BTMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTMD Stock News HeadlinesMay 18 at 4:26 AM | americanbankingnews.comShort Interest in biote Corp. (NASDAQ:BTMD) Increases By 6.8%May 13, 2024 | americanbankingnews.comB. Riley Weighs in on biote Corp.'s FY2024 Earnings (NASDAQ:BTMD)May 11, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for biote Corp. (NASDAQ:BTMD) Reduced by B. RileyMay 9, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q1 2024 Earnings Call TranscriptMay 7, 2024 | msn.comBTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | businesswire.comBiote Reports First Quarter 2024 Financial ResultsMay 7, 2024 | seekingalpha.comEsperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlookApril 29, 2024 | finance.yahoo.comBiote Announces Definitive Settlement with FounderApril 23, 2024 | businesswire.comBiote Schedules First Quarter 2024 Financial Results Release and Conference CallMarch 25, 2024 | msn.comEsperion stock jumps 18% in wake of FDA label expansionsMarch 18, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial ProspectsMarch 14, 2024 | marketwatch.comBiote Soars 22% With Expected Acceleration in 2H 2024 SalesMarch 13, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | finance.yahoo.comBiote Corp (BTMD) Reports Growth Amidst Challenges in Q4 and Full Year 2023March 12, 2024 | businesswire.comBiote Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | benzinga.comPreview: Biote's EarningsFebruary 27, 2024 | finance.yahoo.comBiote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference CallFebruary 27, 2024 | businesswire.comBiote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference CallFebruary 20, 2024 | msn.comBiote announces agreement to resolve litigation with founder Gary DonovitzFebruary 20, 2024 | finance.yahoo.comBiote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s SharesFebruary 20, 2024 | businesswire.comBiote Announces Agreement to Resolve Litigation and Repurchase All of Founder's SharesJanuary 25, 2024 | finance.yahoo.comBiote Announces $20 Million Share Repurchase AuthorizationJanuary 20, 2024 | benzinga.comBiote Stock (NASDAQ:BTMD), Analyst Ratings, Price Targets, PredictionsJanuary 18, 2024 | bizjournals.comBirmingham manufacturer to be acquired for $8.5MJanuary 18, 2024 | realmoney.thestreet.comBiote price target lowered by $1 at Truist, here's whySee More Headlines Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/18/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:BTMD CUSIPN/A CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.11 High Stock Price Target$9.00 Low Stock Price Target$6.55 Potential Upside/Downside+41.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio52.27 Forward P/E Ratio11.06 P/E GrowthN/ANet Income$3.32 million Net Margins4.30% Pretax Margin9.26% Return on Equity-36.67% Return on Assets12.50% Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio4.73 Sales & Book Value Annual Sales$185.36 million Price / Sales1.92 Cash Flow$0.49 per share Price / Cash Flow11.73 Book Value($0.72) per share Price / Book-7.99Miscellaneous Outstanding Shares62,040,000Free Float64,172,000Market Cap$356.73 million OptionableNot Optionable Beta0.87 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Marc D. Beer (Age 59)Executive Chairman Comp: $470.18kMs. Teresa S. Weber (Age 71)CEO & Director Comp: $1.06MMs. Mary Elizabeth Conlon (Age 43)VP of Business Development, General Counsel & Corporate Secretary Comp: $552.36kKey CompetitorsAurora CannabisNASDAQ:ACBDecarbonization Plus Acquisition Co. IVNASDAQ:DCRDAdTheorentNASDAQ:ADTHMind Medicine (MindMed)NASDAQ:MNMDChromaDexNASDAQ:CDXCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 14,615 shares on 5/10/2024Ownership: 1.885%Acadian Asset Management LLCSold 3,406 shares on 5/10/2024Ownership: 0.155%Wasatch Advisors LPSold 402,920 shares on 4/18/2024Ownership: 0.899%Mary Elizabeth ConlonSold 6,240 sharesTotal: $40,560.00 ($6.50/share)View All Insider TransactionsView All Institutional Transactions BTMD Stock Analysis - Frequently Asked Questions Should I buy or sell biote stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for biote in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BTMD shares. View BTMD analyst ratings or view top-rated stocks. What is biote's stock price target for 2024? 5 brokers have issued 12 month target prices for biote's stock. Their BTMD share price targets range from $6.55 to $9.00. On average, they anticipate the company's stock price to reach $8.11 in the next year. This suggests a possible upside of 41.0% from the stock's current price. View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts. How have BTMD shares performed in 2024? biote's stock was trading at $4.94 at the beginning of the year. Since then, BTMD stock has increased by 16.4% and is now trading at $5.75. View the best growth stocks for 2024 here. When is biote's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our BTMD earnings forecast. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) announced its quarterly earnings results on Tuesday, March, 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.06. The company earned $45.70 million during the quarter, compared to analysts' expectations of $45.50 million. biote had a negative trailing twelve-month return on equity of 36.67% and a net margin of 4.30%. What guidance has biote issued on next quarter's earnings? biote issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $202.3 million. Who are biote's major shareholders? biote's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.88%), Wasatch Advisors LP (0.90%) and Acadian Asset Management LLC (0.16%). Insiders that own company stock include Mary Elizabeth Conlon, Roystone Capital Management Lp and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTMD) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersNext President (Not Trump. Not Biden.)The Freeport SocietyA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.